ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Sigma-Aldrich has sold its Pharmorphix solid-form research business to Johnson Matthey, which says the business will expand its European active pharmaceutical ingredient business and clinical supply services. The deal comes as Merck KGaA is expected to close on its $17 billion purchase of Sigma-Aldrich within the next two months. Merck originally planned to complete the transaction by the end of September, but Sigma must sell solvents and inorganics units before the acquisition closes.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X